Table 2.
Clinical Remission and Response at 8 and 52 Weeks after Initiation of TNF-α Inhibitor
| Type of outcomes | Week 8 | Week 52 | |||||
|---|---|---|---|---|---|---|---|
| Infliximab (n=83) |
Adalimumab (n=30) |
p-value | Infliximab (n=83) |
Adalimumab (n=30) |
p-value | ||
| Clinical remission* | 39 (47.0) | 17 (56.7) | 0.364 | 33 (39.8) | 15 (50.0) | 0.331 | |
| Clinical response† | 72 (86.7) | 23 (76.7) | 0.196 | 60 (72.3) | 23 (76.7) | 0.642 | |
| Sustained clinical remission at weeks 8 and 52‡ | NA | NA | 30 (36.1) | 11 (36.7) | 0.959 | ||
| Sustained clinical response at weeks 8 and 52§ | NA | NA | 46 (55.4) | 15 (50.0) | 0.610 | ||
| Partial Mayo score | 2.3±2.2 | 1.8±2.0 | 0.289 | 2.2±2.4 | 1.4±1.7 | 0.060 | |
| Stool frequency subscore | 1.1±1.1 | 0.9±0.9 | 0.371 | 1.1±1.2 | 0.6±0.9 | 0.304 | |
| Rectal bleeding subscore | 0.9±0.7 | 0.4±0.7 | 0.115 | 0.5±0.8 | 0.3±0.7 | 0.298 | |
| PGA subscore | 0.5±0.7 | 0.5±0.8 | 0.809 | 0.5±0.9 | 0.4±0.5 | 0.084 | |
| Change of partial Mayo score from baseline | 4.3±2.5 | 4.1±2.7 | 0.775 | 4.6±2.7 | 4.7±2.3 | 0.786 | |
Data are presented as number (%) or mean±SD.
TNF, tumor necrosis factor; PGA, Physician’s Global Assessment; NA, not available.
*Partial Mayo score ≤1 point; †Decrease in partial Mayo score by at least 2 points from baseline; ‡Patients who were in clinical remission at week 8 and week 52 were considered to be in sustained clinical remission; §Patients who had a clinical response at week 8 and week 52 were considered to have a sustained clinical response.